 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/698213
Australia In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012
|
Description: |
Australia In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012
Summary
This report is an essential source for in-depth information and data relating to the Australia In vitro diagnostic devices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in Australia
Scope
-The report provides in vitro diagnostics information broken down into detailed categories and segments in Australia.
-Total revenues, end users
-Market shares of all the key competitors.
-Key pipeline products that are set to shape the market, broken down by sector.
-Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
-Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
-Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
-Key mergers and acquisitions, partnerships, private equity investments and IPOs.
-Customer, hospitals and physicians data.
Reasons to buy
-Gain a strong understanding of the in vitro diagnostics devices market in Australia.
-Evaluate and compare the attractiveness of the market in the country.
-Identify growth segments and opportunities in each industry sector within the country.
-Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
-Analyze the competitiveness of the market in the country and identify hotspots.
-Develop strategies based on the latest product, brand, expansion and research and development news in the country.
-Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
-Identify and analyze the strengths and weaknesses of the industry incumbents in the country. |
|
Contents: |
1 Table Of Contents 2
1.1 List of Tables 11
1.2 List of Figures 14
2 Introduction 16
2.1 What Is This Report About? 16
3 Definitions of Markets Covered in the Report 17
3.1 In Vitro Diagnostics Devices 17
3.2 Clinical Chemistry Test Reagents 17
3.2.1 Laboratory Reagents 17
3.2.2 Clinical Chemistry Calibrators and Controls 17
3.2.3 Clinical Chemistry Rapid Tests 17
3.3 Immunochemistry Test Reagents 17
3.3.1 Disease Specific Markers 17
3.3.1.1 Tumor Markers 17
3.3.1.2 Cardiac Markers 18
3.3.2 Disease Specific Test Reagents 18
3.3.2.1 Auto-Immune Disease 18
3.3.2.2 Rheumatoid Disease 18
3.3.2.3 Anemia/ Vitamins 18
3.3.2.4 Allergy 18
3.3.3 Drug Related Testing Reagents 18
3.3.3.1 Therapeutic Drugs 18
3.3.3.2 Drug of Abuse and Toxicology 19
3.3.4 Hormone Related Testing Reagents 19
3.3.4.1 Specific Proteins 19
3.3.4.2 Fertility and Pregnancy 19
3.3.4.3 Individual/Specified hormones 19
3.3.4.4 Specific Organ Function 19
3.3.5 Immunochemistry Calibrators and Controls 19
3.3.6 Immunochemistry Rapid Tests 19
3.4 Blood Test Reagents 19
3.4.1 Hematology Test Reagents 19
3.4.1.1 Hematology 20
3.4.1.2 Immunohaematology 20
3.4.1.3 Hematology Calibrators and Controls 20
3.4.1.4 Immunohaematology Controls 20
3.4.2 Hemostasis Test Reagents 20
3.4.2.1 Hemostasis 20
3.4.2.2 Hemostasis Calibrators and Controls 20
3.4.2.3 Hemostasis Rapid Tests 20
3.4.3 Tissue Typing Reagents 20
3.4.4 Monoclonal Antibodies 21
3.4.5 Cytokines and Immunomodulators 21
3.4.6 Histology and Cytology Reagents 21
3.5 Microbiology Test Reagents 21
3.5.1 Bacteriology Test Reagents 21
3.5.1.1 Bacteriology Culture 21
3.5.1.2 Blood Culture 21
3.5.1.3 Bacteriology Identification and Susceptibility 21
3.5.2 Microbiology Calibrators and Controls 21
3.5.3 Microbiology Rapid Tests 22
3.6 Infectious Immunology Test Reagents 22
3.6.1 Bacteriology 22
3.6.2 Virology 22
3.6.2.1 Hepatitis Viruses 22
3.6.2.2 Retroviruses 22
3.6.3 Parasitology 22
3.6.4 Infectious Immunology Calibrators and Controls 22
3.6.5 Infectious Immunology Rapid Tests 22
3.7 Genetic Test Reagents 22
3.8 Self Testing 23
3.9 Instruments 23
4 Healthcare Sector Review 24
4.1 Healthcare Expenditure 24
4.2 Healthcare Infrastructure 27
4.3 Healthcare Policy 31
5 Regulation System 32
5.1 Medical Equipment Approval Process 32
5.1.1 Classification 32
5.1.2 Registration and Conformity Assessment 39
5.2 Advertising 41
5.3 Labeling and Packaging 42
5.4 Post-market Surveillance 43
5.5 Registration Fee 43
6 Pricing and Reimbursement 50
7 Distribution Structure 51
8 In Vitro Diagnostics In Australia 52
8.1 In Vitro Diagnostics Cross Country Comparison (2000-2012) 52
8.2 In Vitro Diagnostics, Australia, Overall Revenues ($ mn), 2000-2012 53
8.3 In Vitro Diagnostics, Australia Company share (2006-2007) 59
9 Blood Test Reagents In Australia 60
9.1 Blood Test Reagents Overall Revenue (2000-2012) 60
9.1.1 Haematology Test Reagents Revenue (2000-2012) 64
9.1.2 Hemostasis Test Reagents Revenue (2000-2012) 66
9.2 Blood Test Reagents Distribution Share (2006-2007) 68
9.3 Blood Test Reagents, Australia, Company Share (2006-2007) 69
10 Clinical Chemistry Test Reagents In Australia 70
10.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2012) 70
10.2 Clinical Chemistry Test Reagents Distribution Share (2006-2007) 72
10.3 Clinical Chemistry Test Reagents, Australia, Company Share (2006-2007) 73
11 Genetic Test Reagents In Australia 74
11.1 Genetic Test Reagents Overall Revenue (2000-2012) 74
11.2 Genetic Test Reagents Distribution Share (2006-2007) 76
11.3 Genetic Test Reagents, Australia, Company Share (2006-2007) 77
12 Immunochemistry Test Reagents In Australia 78
12.1 Immunochemistry Test Reagents Overall Revenue (2000-2012) 78
12.1.1 Disease Specific Markers Revenue (2000-2012) 82
12.1.2 Disease Specific Test Reagents Revenue (2000-2012) 84
12.1.3 Drug Related Testing Reagents Revenue (2000-2012) 86
12.1.4 Hormone Related Testing Reagents Revenue (2000-2012) 88
12.2 Immunochemistry Test Reagents Distribution Share (2006-2007) 90
12.3 Immunochemistry Test Reagents, Australia, Company Share (2006-2007) 91
13 Infectious Immunology Test Reagents In Australia 92
13.1 Infectious Immunology Test Reagents Overall Revenue (2000-2012) 92
13.1.1 Virology Revenue (2000-2012) 96
13.2 Infectious Immunology Test Reagents Distribution Share (2006-2007) 98
13.3 Infectious Immunology Test Reagents, Australia, Company Share (2006-2007) 99
14 Instruments In Australia 100
14.1 Instruments Overall Revenue (2000-2012) 100
14.2 Instruments Distribution Share (2006-2007) 102
15 Microbiology Test Reagents In Australia 103
15.1 Microbiology Test Reagents Overall Revenue (2000-2012) 103
15.1.1 Bacteriology Test Reagents Revenue (2000-2012) 105
15.2 Microbiology Test Reagents Distribution Share (2006-2007) 107
15.3 Microbiology Test Reagents, Australia, Company Share (2006-2007) 108
16 Self Testing In Australia 109
16.1 Self Testing Overall Revenue (2000-2012) 109
16.2 Self Testing Distribution Share (2006-2007) 111
16.3 Self Testing, Australia, Company Share (2006-2007) 112
17 F. Hoffmann-La Roche Ltd. Company Profile 113
17.1 Company Overview 113
17.2 Value Chain Analysis 114
17.2.1 Manufacturing 114
17.2.1.1 In House Manufacturing 114
17.2.1.2 Outsourcing 114
17.2.2 Product Development 115
17.2.2.1 Regulatory Approvals 115
17.2.2.2 Clinical Trials 115
17.2.2.3 Research and Development 115
17.2.3 Sales and Marketing 116
17.2.3.1 Partnerships and Alliances 116
17.2.3.2 Licensing Agreements 116
18 Abbott Laboratories Company Profile 117
18.1 Company Overview 117
18.2 Value Chain Analysis 118
18.2.1 Manufacturing 118
18.2.1.1 In House Manufacturing 118
18.2.2 Product Development 118
18.2.2.1 Regulatory Approvals 118
18.2.2.2 Research and Development 118
18.2.2.3 Clinical Trials 119
18.2.3 Sales and Marketing 120
18.2.3.1 Partnerships and Alliances 120
19 Beckman Coulter, Inc. Company Profile 121
19.1 Company Overview 121
19.2 Value Chain Analysis 122
19.2.1 Manufacturing 122
19.2.1.1 In House Manufacturing 122
19.2.2 Product Development 122
19.2.2.1 Regulatory Approvals 122
19.2.2.2 Research and Development 123
19.2.3 Sales and Marketing 123
19.2.3.1 Partnerships and Alliances 123
19.2.3.2 Licensing Agreements 123
19.3 Beckman Coulter, Inc. Pipeline Products 124
19.3.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type 124
19.3.2 Beckman Coulter, Inc. Pipeline Products By Development Stage 125
19.3.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area 126
19.3.4 Beckman Coulter, Inc. Pipeline Products By News Summary 126
20 Dade Behring Holdings, Inc. Company Profile 127
20.1 Company Overview 127
20.2 Dade Behring Holdings, Inc. Pipeline Products 127
20.2.1 Dade Behring Holdings, Inc. Pipeline Products By Equipment Type 127
20.2.2 Dade Behring Holdings, Inc. Pipeline Products By Equipment Type 127
20.2.3 Dade Behring Holdings, Inc. Pipeline Products By Therapy Area 127
20.2.4 Dade Behring Holdings, Inc. Pipeline Products By News Summary 127
21 Ortho-Clinical Diagnostics Inc. Company Profile 128
21.1 Company Overview 128
22 bioMerieux S.A. Company Profile 129
22.1 Company Overview 129
22.2 Value Chain Analysis 130
22.2.1 Manufacturing 130
22.2.1.1 In House Manufacturing 130
22.2.2 Product Development 131
22.2.2.1 Regulatory Approvals 131
22.2.2.2 Clinical Trials 131
22.2.2.3 Research and Development 131
22.2.3 Sales and Marketing 131
22.2.3.1 Partnerships and Alliances 131
22.2.3.2 Licensing Agreements 131
23 Astral Scientific Pty Ltd Company Profile 133
23.1 Company Overview 133
24 Banksia Scientific Pte Ltd Company Profile 134
24.1 Company Overview 134
25 Diagnostic Technology Company Profile 135
25.1 Company Overview 135
26 Enterix Australia Pty Ltd Company Profile 136
26.1 Company Overview 136
27 Fermiscan Holdings Limited Company Profile 137
27.1 Company Overview 137
27.2 Fermiscan Holdings Limited Pipeline Products 137
27.2.1 Fermiscan Holdings Limited Pipeline Products By Equipment Type 137
27.2.2 Fermiscan Holdings Limited Pipeline Products By Development Stage 137
27.2.3 Fermiscan Holdings Limited Pipeline Products By Therapy Area 137
27.2.4 Fermiscan Holdings Limited Pipeline Products By Clinical Trials 138
27.2.5 Fermiscan Holdings Limited Pipeline Products By News Summary 138
28 Flinders Technologies Pty Ltd Company Profile 139
28.1 Flinders Technologies Pty Ltd Pipeline Products 139
28.1.1 Flinders Technologies Pty Ltd Pipeline Products By Equipment Type 139
28.1.2 Flinders Technologies Pty Ltd Pipeline Products By Development Stage 139
28.1.3 Flinders Technologies Pty Ltd Pipeline Products By Therapy Area 139
29 GeneWorks Pty. Ltd. Company Profile 140
29.1 Company Overview 140
30 LabTech Systems Limited Company Profile 141
30.1 Company Overview 141
31 Panbio Limited Company Profile 142
31.1 Company Overview 142
31.2 Panbio Limited Pipeline Products 142
31.2.1 Panbio Limited Pipeline Products By Equipment Type 142
31.2.2 Panbio Limited Pipeline Products By Development Stage 142
31.2.3 Panbio Limited Pipeline Products By Therapy Area 143
31.2.4 Panbio Limited Pipeline Products By News Summary 143
32 Proteome Systems Limited Company Profile 144
32.1 Company Overview 144
32.2 Proteome Systems Limited Pipeline Products 144
32.2.1 Proteome Systems Limited Pipeline Products By Equipment Type 144
32.2.2 Proteome Systems Limited Pipeline Products By Development Stage 144
32.2.3 Proteome Systems Limited Pipeline Products By Therapy Area 145
32.2.4 Proteome Systems Limited Pipeline Products By News Summary 145
33 Universal Biosensors, Inc. Company Profile 146
33.1 Company Overview 146
33.2 Universal Biosensors, Inc. Pipeline Products 146
33.2.1 Universal Biosensors, Inc. Pipeline Products By Equipment Type 146
33.2.2 Universal Biosensors, Inc. Pipeline Products By Development Stage 146
33.2.3 Universal Biosensors, Inc. Pipeline Products By Therapy Area 146
34 Vision BioSystems Ltd Company Profile 147
34.1 Company Overview 147
35 Financial Deals Landscape 148
35.1 Acquisition 148
35.1.1 QIAGEN Acquires Corbett Life Science 148
35.2 Equity Offerings 149
35.2.1 Proteome Systems Completes Private Placement Of $2.17 Million 149
35.2.2 CSL Completes Private Placement Of $1517.63 Million 151
36 Recent Developments 153
36.1 Product News 153
36.1.1 Jul 16, 2008: Proteome Systems Reports Proof Of Concept Study Results For Prostate Cancer Diagnostic Program 153
37 Appendix 154
37.1 Global Markets Direct Research Methodology 154
37.2 Coverage 155
37.3 Secondary Research 155
37.4 Primary Research 156
37.5 Models 156
37.6 Forecasts 157
37.7 Expert Panels 157
37.8 Currency Conversion 158
37.9 Contact Us 159
37.10 Disclaimer 159
Executive Summary
1.1 List of Tables
Table 1: Healthcare Infrastructure in Australia, 2005 27
Table 2: Healthcare Personnel in Australia, 2005 28
Table 3: Hospital Wards by Specialty in Australia, 2003-2007 29
Table 4: Doctors by Specialty in Australia, 2003-2007 30
Table 5: Conformity Assessment of Medical Devices based Device Class, in Australia, 2007 41
Table 6: Fee for Registered Device in Australia, 2007 43
Table 7: Fee for Device Clinical Trial in Australia, 2007 44
Table 8: Evaluation Fee for High and Low Level Registration of Medical Device in Australia, 2007 44
Table 9: Evaluation Fee for Variation Registration of Medical Device in Australia, 2007 45
Table 10: Fee for Registration of Listed Devices in Australia, 2007 45
Table 11: Fee for Registration of Listed Devices for Export Only in Australia, 2007 46
Table 12: Fee for Registration of Included Devices in Australia, 2007 46
Table 13: Fee for Initial Conformity Assessment of Medical Device in Australia, 2007 46
Table 14: Fee for Medical Device Changes Conformity Assessment in Australia, 2007 47
Table 15: Fee for Medical Device Conformity Assessment Surveillance Audit in Australia, 2007 47
Table 16: Fee for Medical Device Conformity Assessment Review Certificate in Australia, 2007 47
Table 17: Fee for Initial Conformity Assessment of Medical Device Components in Australia, 2007 48
Table 18: Fee for Conformity Assessment of Changes in Medical Device Components in Australia, 2007 48
Table 19: Fee for Abridged Conformity Assessment of Medical Device Components in Australia, 2007 48
Table 20: Fee for Inclusion of Medical Device in the Register in Australia, 2007 49
Table 21: Fee for ARTG Inclusion for Medical Device in Australia, 2007 49
Table 22: In Vitro Diagnostics Cross Country Comparison (2000-2012) 52
Table 23: In Vitro Diagnostics, Australia, Overall Revenues ($ mn), 2000-2012 53
Table 24: In Vitro Diagnostics, Australia, Portfolio Analysis, 2000-2012 54
Table 25: In Vitro Diagnostics, Australia, Overall Revenues ($ mn), Historic, 2000-2007 56
Table 26: In Vitro Diagnostics, Australia, Overall Revenues ($ mn), Forecast, 2007-2012 58
Table 27: In Vitro Diagnostics, Australia Company share by Revenue ($ mn), 2006-2007 59
Table 28: Blood Test Reagents, Australia, Revenue ($ mn) by Segment , Historic, 2000-2007 61
Table 29: Blood Test Reagents, Australia, Revenue ($ mn) by Segment , Forecast, 2007-2012 63
Table 30: Haematology Test Reagents, Australia, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 64
Table 31: Haematology Test Reagents, Australia, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 65
Table 32: Hemostasis Test Reagents, Australia, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 66
Table 33: Hemostasis Test Reagents, Australia, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 67
Table 34: Blood Test Reagents, Australia, Distribution Share by Revenue ($mn), 2006-2007 68
Table 35: Blood Test Reagents, Australia, Company Share by Revenue ($ mn), 2006-2007 69
Table 36: Clinical Chemistry Test Reagents, Australia, Revenue ($ mn) by Segment , Historic, 2000-2007 70
Table 37: Clinical Chemistry Test Reagents, Australia, Revenue ($ mn) by Segment , Forecast, 2007-2012 71
Table 38: Clinical Chemistry Test Reagents, Australia, Distribution Share by Revenue ($mn), 2006-2007 72
Table 39: Clinical Chemistry Test Reagents, Australia, Company Share by Revenue ($ mn), 2006-2007 73
Table 40: Genetic Test Reagents, Australia, Revenue ($ mn) by Segment , Historic, 2000-2007 74
Table 41: Genetic Test Reagents, Australia, Revenue ($ mn) by Segment , Forecast, 2007-2012 75
Table 42: Genetic Test Reagents, Australia, Distribution Share by Revenue ($mn), 2006-2007 76
Table 43: Genetic Test Reagents, Australia, Company Share by Revenue ($ mn), 2006-2007 77
Table 44: Immunochemistry Test Reagents, Australia, Revenue ($ mn) by Segment , Historic, 2000-2007 79
Table 45: Immunochemistry Test Reagents, Australia, Revenue ($ mn) by Segment , Forecast, 2007-2012 81
Table 46: Disease Specific Markers, Australia, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 82
Table 47: Disease Specific Markers, Australia, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 83
Table 48: Disease Specific Test Reagents, Australia, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 84
Table 49: Disease Specific Test Reagents, Australia, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 85
Table 50: Drug Related Testing Reagents, Australia, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 86
Table 51: Drug Related Testing Reagents, Australia, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 87
Table 52: Hormone Related Testing Reagents, Australia, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 88
Table 53: Hormone Related Testing Reagents, Australia, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 89
Table 54: Immunochemistry Test Reagents, Australia, Distribution Share by Revenue ($mn), 2006-2007 90
Table 55: Immunochemistry Test Reagents, Australia, Company Share by Revenue ($ mn), 2006-2007 91
Table 56: Infectious Immunology Test Reagents, Australia, Revenue ($ mn) by Segment , Historic, 2000-2007 93
Table 57: Infectious Immunology Test Reagents, Australia, Revenue ($ mn) by Segment , Forecast, 2007-2012 95
Table 58: Virology, Australia, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 96
Table 59: Virology, Australia, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 97
Table 60: Infectious Immunology Test Reagents, Australia, Distribution Share by Revenue ($mn), 2006-2007 98
Table 61: Infectious Immunology Test Reagents, Australia, Company Share by Revenue ($ mn), 2006-2007 99
Table 62: Instruments, Australia, Revenue ($ mn) by Segment , Historic, 2000-2007 100
Table 63: Instruments, Australia, Revenue ($ mn) by Segment , Forecast, 2007-2012 101
Table 64: Instruments, Australia, Distribution Share by Revenue ($mn), 2006-2007 102
Table 65: Microbiology Test Reagents, Australia, Revenue ($ mn) by Segment , Historic, 2000-2007 103
Table 66: Microbiology Test Reagents, Australia, Revenue ($ mn) by Segment , Forecast, 2007-2012 104
Table 67: Bacteriology Test Reagents, Australia, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 105
Table 68: Bacteriology Test Reagents, Australia, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 106
Table 69: Microbiology Test Reagents, Australia, Distribution Share by Revenue ($mn), 2006-2007 107
Table 70: Microbiology Test Reagents, Australia, Company Share by Revenue ($ mn), 2006-2007 108
Table 71: Self Testing, Australia, Revenue ($ mn) by Segment , Historic, 2000-2007 109
Table 72: Self Testing, Australia, Revenue ($ mn) by Segment , Forecast, 2007-2012 110
Table 73: Self Testing, Australia, Distribution Share by Revenue ($mn), 2006-2007 111
Table 74: Self Testing, Australia, Company Share by Revenue ($ mn), 2006-2007 112
Table 75: Beckman Coulter, Inc. Pipeline Products by Equipment Type 124
Table 76: Beckman Coulter, Inc. Pipeline Products By Development Stage 125
Table 77: Beckman Coulter, Inc. Pipeline Products By Therapy Area 126
Table 78: Beckman Coulter, Inc. Pipeline Products By News Summaries 126
Table 79: Dade Behring Holdings, Inc. Pipeline Products by Equipment Type 127
Table 80: Dade Behring Holdings, Inc. Pipeline Products by Equipment Type 127
Table 81: Dade Behring Holdings, Inc. Pipeline Products By Therapy Area 127
Table 82: Dade Behring Holdings, Inc. Pipeline Products By News Summaries 127
Table 83: Fermiscan Holdings Limited Pipeline Products by Equipment Type 137
Table 84: Fermiscan Holdings Limited Pipeline Products by Development Stage 137
Table 85: Fermiscan Holdings Limited Pipeline Products By Therapy Area 137
Table 86: Fermiscan Holdings Limited Pipeline Products By Clinical Trials 138
Table 87: Fermiscan Holdings Limited Pipeline Products By News Summaries 138
Table 88: Flinders Technologies Pty Ltd Pipeline Products by Equipment Type 139
Table 89: Flinders Technologies Pty Ltd Pipeline Products By Development Stage 139
Table 90: Flinders Technologies Pty Ltd Pipeline Products By Therapy Area 139
Table 91: Panbio Limited Pipeline Products by Equipment Type 142
Table 92: Panbio Limited Pipeline Products By Development Stage 142
Table 93: Panbio Limited Pipeline Products By Therapy Area 143
Table 94: Panbio Limited Pipeline Products By News Summaries 143
Table 95: Proteome Systems Limited Pipeline Products by Equipment Type 144
Table 96: Proteome Systems Limited Pipeline Products by Development Stage 144
Table 97: Proteome Systems Limited Pipeline Products By Therapy Area 145
Table 98: Proteome Systems Limited Pipeline Products By News Summaries 145
Table 99: Universal Biosensors, Inc. Pipeline Products by Equipment Type 146
Table 100: Universal Biosensors, Inc. Pipeline Products By Development Stage 146
Table 101: Universal Biosensors, Inc. Pipeline Products By Therapy Area 146
Table 102: QIAGEN Acquires Corbett Life Science 148
Table 103: Proteome Systems Completes Private Placement Of $2.17 Million 149
Table 104: CSL Completes Private Placement Of $1517.63 Million 151
Table 105: Currency Conversion from USD to Local Currency at 2007 Constant Rate 158 |
|
Companies Mentioned |
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Beckman Coulter, Inc.
Dade Behring Holdings, Inc.
Ortho-Clinical Diagnostics Inc.
bioMerieux S.A.
Astral Scientific Pty Ltd
Banksia Scientific Pte Ltd
Diagnostic Technology
Enterix Australia Pty Ltd
Fermiscan Holdings Limited
Flinders Technologies Pty Ltd
GeneWorks Pty. Ltd.
LabTech Systems Limited
Panbio Limited
Proteome Systems Limited
Universal Biosensors, Inc.
Vision BioSystems Ltd Company Profile |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/698213
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 30/11/2009 01:45:53 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Australia In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012
|
|
Web Address: |
http://www.researchandmarkets.com/reports/698213
|
|
Office Code: |
|
OC8HJNPOUMUXU
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Single User
|
|
€2,015.00
|
|
Electronic (PDF)
- Site License
|
|
€4,030.00
|
|
Electronic (PDF)
- Enterprisewide
|
|
€6,044.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 30/11/2009 01:45:53
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
